INTRODUCTION
The ribosome assembles amino acids into polypeptides in the peptidyl transferase center (PTC) located at the interface side of the large ribosomal subunit. The nascent peptide is threaded through the exit tunnel, which spans the entire body of the subunit and opens at its solvent side. On its way through the tunnel, whose walls are built primarily of rRNA, the nascent peptide can interact with a number of RNA residues. At the same time, segments of several ribosomal proteins are exposed in the tunnel lumen. In particular, loops of two proteins, L4 and L22, contribute to formation of a constriction in the tunnel located $30 Å away from the PTC (Berisio et al., 2003; Gabashvili et al., 2001; Harms et al., 2001; Jenni and Ban, 2003; Mitra et al., 2006; Nissen et al., 2000) .
Most proteins are thought to smoothly pass through the tunnel on their way out. However, accumulating evidence shows that some nascent polypeptides establish specific interactions with tunnel elements, resulting in ribosome stalling. In several characterized cases, stalling regulates gene expression (Cao and Geballe, 1996; Gong and Yanofsky, 2002; Nakatogawa and Ito, 2002; Onouchi et al., 2005; Wang and Sachs, 1997) . Ribosome stalling during translation of the secretion monitor gene secM in Escherichia coli controls the expression of the downstream secA cistron, which encodes a component of the secretion apparatus. When a specific sequence of the SecM nascent peptide is synthesized and properly placed in the exit tunnel, it induces a conformational change in the ribosome, resulting in ribosome stalling (Mitra et al., 2006; Muto et al., 2006; Nakatogawa and Ito, 2002) . If the cellular secretion is lethargic, the stalling persists for a long time, leading to activation of secA expression (Nakatogawa and Ito, 2001 ). In another well-characterized example in bacteria, ribosome stalling is used for regulation of expression of tryptophan catabolizing enzymes (Gong and Yanofsky, 2002) . In the presence of high concentrations of tryptophan, the ribosome stalls at the last sense codon of the tnaC cistron, occluding the transcription terminator and activating the expression of the downstream genes (Gong et al., 2001; Gong and Yanofsky, 2002) . Specific interactions of the TnaC nascent peptide with the tunnel mediate formation of a long-lived stalled complex and inhibition of peptide release.
Though ribosome stalling has received a surge of attention in the past few years, the first example of nascent peptide-dependent translation arrest was described more than a quarter century ago when Weisblum and Dubnau laboratories characterized inducible expression of the erythromycin resistance genes (Gryczan et al., 1980; Horinouchi and Weisblum, 1980) . Erythromycin and other macrolide antibiotics bind in the nascent peptide tunnel in the vicinity of the PTC and are thought to block translation by inhibiting progression of the nascent peptide when it reaches the size of 3-9 amino acids long (Tenson et al., 2003; Vazquez, 1975) . The inducible ermC cassette, which is often found in resistant pathogens, consists of the resistance methyltransferase gene (ermC) preceded by a 19-codon open reading frame (ORF) encoding the regulatory leader peptide ErmCL (Figures 1A and 1B) . In the absence of an inducing antibiotic, ermC expression is repressed because its ribosome binding site is sequestered in the mRNA secondary structure. Subinhibitory concentrations of an inducer (erythromycin or similar macrolide antibiotics) cause the ribosome to stall at the ermCL ORF, triggering a conformational change in the mRNA that releases the ermC ribosome binding site, and thus activates the expression of the methylase gene (Horinouchi and Weisblum, 1980; Narayanan and Dubnau, 1985) . Because nonsense mutations beyond the 10th codon of the leader ORF do not alleviate induction, it has been suggested that only a portion of the leader peptide is required for stalling (Mayford and Weisblum, 1989 ).
Mutational analyses have also shown that changes in the first few amino acids of the leader had little effect on inducibility, but alterations of residues Ile-6, Phe-7, and Val-8 severely impair it (Mayford and Weisblum, 1989) . Though the precise stalling point has not been determined, the results of the mutational studies implied that in the stalled complex the ermCL nascent peptide would be only a few amino acids long (Mayford and Weisblum, 1989; Weisblum, 1995) . Therefore, drug-dependent ribosome stalling on the ermC leader seemed to be principally different from the stalling at SecM or TnaC nascent peptides, which span the entire length of the tunnel and do not require the presence of antibiotic.
In spite of the time passed since the discovery of inducible erm genes, very little has been learned about the molecular mechanisms of ribosome stalling, which is at the heart of the translation attenuation model of antibiotic induction. Several key questions remained essentially unanswered: why do some macrolide antibiotics efficiently induce erm expression, while other similar drugs act as much poorer inducers? If macrolide antibiotics block translation of all polypeptides, why does the sequence of the nascent peptide matter for stalling? Which elements of the ribosome are involved in stalling? Which step in translation is blocked in the stalled complex? How does stalling on the ermCL ORF compare with stalling on the tnaC or secM cistrons?
In order to get insights into the molecular details of drug-dependent ribosome stalling, we took a biochemical approach to study stalling of the ribosome during translation of the ermC leader peptide. By analyzing the nature and placement of peptidyl-tRNA in the stalled ribosome, and detecting the presence and exact position of the stalled complex on ermCL mRNA, we gained important information on how the stalling mechanism may operate. Combining biochemical data with the knowledge of the structure of the ribosome tunnel, we were able to identify some of the key molecular players involved in the translation arrest.
RESULTS
Erythromycin-Dependent Induction of ermC in the E. coli Cell-Free Translation System Inducible expression of ermC was originally characterized in Gram-positive bacteria (Horinouchi and Weisblum, 1980; Shivakumar et al., 1980) , and subsequent studies have shown that ermC can be inducibly expressed in E. coli cells (Bailey et al., 2008; Hardy and Haefeli, 1982) . Because our experimental strategy required the use of an E. coli cell-free system, it was important to test whether erythromycin-dependent inducible expression of ermC could be reproduced in vitro (Shimizu et al., 2001) . When a bicistronic DNA template containing the leader peptide ermCL and methylase ermC ORFs was expressed in the in vitro transcription-translation system in the absence of erythromycin, the main translation product corresponded to the 2.2 kDa leader peptide, whereas no ErmC was synthesized ( Figure 1C ). Only when erythromycin was present did translation of a 29 kDa polypeptide representing a full-size ErmC became evident. In agreement with in vivo data (Mayford and Weisblum, 1990; Narayanan and Dubnau, 1985) , induction of ermC expression in vitro was observed only within a specific range of erythromycin concentrations (0.05-2 mM) ( Figure 1D ). At very low drug concentrations ribosome stalling at the leader ORF is apparently inefficient, whereas at high concentrations erythromycin inhibits translation altogether.
These results show that inducible expression of ermC can be faithfully reproduced in vitro, therefore demonstrating that all the elements required for ribosome stalling at the ermCL ORF are present in the E. coli cell-free system.
The Site of Ribosome Stalling on the ermC Leader mRNA The key element of the ermC induction model is the erythromycin-dependent ribosome stalling on the leader ORF. However, not only has the exact stalling site remained unknown, but the existence of the stalled ribosome complex on the leader mRNA has never been directly shown. Here, we used the toeprinting technique (Hartz et al., 1988; Muto et al., 2006) to test whether the stalled complex exists and is stable enough to block reverse transcriptase progression; toe-printing could also help to determine the exact position of the stalled ribosome on mRNA. The ermCL ORF controlled by a T7 promoter was transcribed and translated in the cell-free system in the absence or presence of erythromycin. Subsequently, a radiolabeled primer was annealed to the 3 0 -proximal region of the leader ORF transcript and extended by reverse transcriptase. The reaction products were resolved on a denaturing polyacrylamide gel (Figure 1E ). When erythromycin was present at sufficiently high concentrations, a strong reverse transcriptase stop was observed at positions +40 and +41 relative to the 5 0 end of the ermCL ORF ( Figure 1B) . A clear toe-printing signal was observed already at 0.2 mM erythromycin, and its strength increased with increasing concentration of the drug. This result revealed the erythromycindependent formation of a stable stalled complex on the leader mRNA. Because in the assay reverse transcriptase stops 16 to 17 residues away from the first nucleotide of the P site codon (Hartz et al., 1988) , the observed signal places the Ile9 codon in the P site and the Ser10 codon at the A site of the stalled ribosome.
Placement of Peptidyl-tRNA in the Stalled Complex
The toe-printing data described above are compatible with two versions of the stalled complex. If the ribosome stalls after the translocation step, then peptidyl-tRNA Ile , carrying a 9 amino acid-long nascent peptide with a C-terminal isoleucine, is expected to be in the classic P/P state. Alternatively, if the stalled ribosome is trapped in the pretranslocation state, the 10 amino acid-long peptidyl-tRNA Ser (having serine as its C-terminal amino acid) will reside either in the A/A site or in the A/P hybrid state (Moazed and Noller, 1989) . In order to distinguish between these possibilities, we used amino acid-specific labeling to define the nature of the C-terminal peptide residue of the peptidyl-tRNA in the stalled complex.
Ribosome stalling in the cell-free translation system should lead to the accumulation of a specific peptidyl-tRNA trapped in the stalled complex. Indeed, when products of the translation reaction (directed by the ermCL ORF and carried out in the presence of [ 35 S]methionine) were separated by gel electrophoresis in
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Drug-Dependent Ribosome Stalling a buffer system that preserved the integrity of the peptidyl-tRNA ester bond, a slow-migrating band was observed (Figure 2A ). The appearance of this radioactive band depended on the presence of erythromycin, suggesting that it represented a protein-containing component of the stalled complex. At the same time, the material in the band was RNase sensitive, showing that the protein was linked to RNA. Upon phenol extraction this material partitioned into the aqueous phase-an indication that its protein component was a short peptide or an amino acid (Figure 2A ). Finally, the electrophoretic mobility of this band was slower than that of [ 35 S]fMet-tRNA ( Figure 2B ), which led to the conclusion that this material represented peptidyl-tRNA from the stalled ribosome complex. The accumulating peptidyl-tRNA was largely resistant to the action of peptidyl-tRNA hydrolase, which argued that most of it remained tightly associated with the ribosome rather than being a drop-off product (N.V.-L. and A.S.M., unpublished data).
The ermCL ORF contains three isoleucine codons (positions 3, 6, and 9). In order to obtain a leader peptide ORF variant with Ile9 as the sole isoleucine codon, the sequence of codons 3 and 6 was changed from ATT (Ile) to CTT (Leu). These mutations (I3L/ I6L) did not affect formation of the erythromycin-induced stalled complex ( Figure 2C ). Next, the wild-type and the I3L/I6L mutant ermCL ORFs were translated in the cell-free system in the presence of [ 14 C]Ile. In both cases, the accumulation of 14 C-labeled peptidyl-tRNA was readily observed ( Figure 2D ), confirming that peptidyl-tRNA in the stalled complex carries at least a 9 amino acid-long nascent peptide. A similar approach was used to determine whether Ser10 is incorporated into the peptidyltRNA in the stalled complex. The ermCL sequence contains two serine codons, Ser5 and Ser10. The Ser5 codon (AGT) was mutated to an Ala codon (GCT), and toe-printing analysis was again used to verify that this mutation allowed formation of the stalled complex ( Figure 2C ). In agreement with this result, when expression of S5A leader template was carried out in the presence of [
35 S]Met, erythromycin-dependent accumulation of peptidyl-tRNA was observed ( Figure 2E ). However, when the same reaction was carried out in the presence of [ 14 C]Ser, radioactive peptidyl-tRNA was seen only with the wild-type template (reflecting incorporation of Ser5), but not with the S5A mutant. This result shows that in the stalled complex, peptide bond formation between Ile9 and Ser10 does not take place and Ile9 remains the last amino acid residue incorporated in the nascent peptide before translation is arrested. Combining these data with the results of the toe-printing analysis, we concluded that peptidyl-tRNA Ile , carrying a 9 amino acid-long peptide MGIFSIFVI, is positioned in the P/P site of the arrested ribosome.
The Stalled Ribosome Is Unable to Catalyze Peptide Bond Formation
The presence of peptidyl-tRNA in the P site argued that the stalled ribosome might be impaired in peptide bond formation. Indeed, treatment of the stalled complex with puromycin, which is expected to release the nascent peptide upon peptide bond formation, had no effect on the toe-printing signal, indicating that the stalled ribosome is refractory to the action of this antibiotic (data not shown). To verify this observation, we prepared stalled complex on ermCL mRNA truncated immediately after the Ile9 codon. Because of the lack of tmRNA in the system, the ribosomes that reach the Ile9 codon at the 3 0 end of the truncated mRNA should remain associated with it and with peptidyltRNA, even in the absence of erythromycin. In the presence of erythromycin, an authentic stalled complex is expected to assemble on truncated ermCL mRNA. Both types of complexes were treated with 1 mM puromycin, and peptidyl-tRNA was analyzed by gel electrophoresis ( Figure 2F ). Puromycin easily released the nascent peptide from the peptidyl-tRNA in the complex formed in the absence of erythromycin. In contrast, the stalled complex with erythromycin was refractory to puromycin action. The most straightforward explanation of these results is that the stalled ribosome is unable to catalyze peptide bond formation.
Structural Elements of the Nascent Peptide Critical for Stalling
Mutational studies have shown the importance of amino acid residues 6-8 of the leader peptide for induction of ermC expression (Mayford and Weisblum, 1989) . Although illuminating, these results could not readily distinguish between the effects of mutations on mRNA conformation versus ribosome stalling. The toeprinting assay provides a more precise tool to investigate the properties of the nascent peptide that directly affect formation of the stalled complex. In order to identify the amino acid residues important for stalling, we performed alanine-scanning 
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Drug-Dependent Ribosome Stalling mutagenesis of the Gly2-Ser10 segment of the leader peptide and used toe-printing to monitor the ability of mutant nascent peptides to stall the ribosome ( Figure 3A) . Alanine substitutions at residues 2-5 or the mutation of Ser10 to alanine did not prevent erythromycin-dependent translation arrest. On the other hand, substitutions of residues Ile6, Phe7, Val8, or Ile9 for Ala abolished stalling. These results show that the C-terminal segment of the leader peptide is the most critical for erythromycindependent ribosome stalling. The importance of the C-terminal amino acid of the nascent peptide, located within the PTC active site, confirmed our conclusion that the PTC is likely the target point of the stalling mech- anism. Because substitution of Ala for Ile9 introduces a rather dramatic change in the amino acid structure, we tested whether a more conservative change, Ile9 to Leu, would also affect formation of the stalled complex. The toe-printing result shows that even a relatively minor alteration in the structure of the P site amino acid residue prevents stalling ( Figure 3A , right panel) re-emphasizing the notion of the PTC importance in stalling. Mutations in codon 9 of the mRNA affect not only the P site amino acid, but also the tRNA moiety of the peptidyl-tRNA, which hypothetically may also affect stalling. However, substitution of the AUC 9 codon, decoded by tRNA 1 Ile , with the AUA codon, decoded by tRNA 2 Ile , did not eliminate stalling (data not shown). Therefore, the structure of the tRNA does not appear to be critical, whereas the nature of the C-terminal amino acid of the nascent peptide constitutes a key element in the mechanism of stalling.
The length of the ErmCL nascent peptide in the stalled complex is much shorter than that of the SecM and TnaC stalling peptides. Even though the alanine scanning showed that only the sequence of the four C-terminal amino acids of the ErmCL is critical for stalling, we wondered whether the N terminus of the ErmCL nascent peptide plays any role in stalling. Site-directed mutagenesis was used to delete one (Gly2), two (Gly2-Ile3), or three (Gly2-Ile3-Phe4) codons in the leader ORF. Similarly, another set of templates was prepared by introducing one, two, or three extra alanine codons GCG after the initiator codon of the ermCL ORF. Toe-printing analysis showed that, regardless of the codon deletions or additions, the site of stalling did not change: translation was always arrested at the same Ile codon corresponding to Ile9 in the wild-type leader sequence. Thus, the IFVI C-terminal sequence of the nascent peptide defines the stalling site and constitutes a strict prerequisite for the formation of the stalled complex ( Figure 3B ). However, changing the length of the nascent peptide dramatically reduced the efficiency of stalling ( Figure 3C ). This result leads to the conclusion that, although the N-terminal sequence of the ErmCL peptide is not critical, the N terminus has to reach a particular place in the tunnel to promote stalling.
Specific Features of the Antibiotic Required for Stalling
The initial studies of ermC induction have demonstrated the importance of the structure of the inducing macrolide antibiotic (Mayford and Weisblum, 1990) . More recently, the newest generation of clinical macrolides, the ketolides, have been praised for their lower erm-inducing activity compared to macrolides of previous generations (Bonnefoy et al., 1997; Bryskier, 2000) . The inability of ketolides to induce erm was tentatively linked to the lack of a C3 cladinose sugar, which in ketolides is replaced with a keto group (Clarebout and Leclercq, 2002) (Figure 4, top) . The dissimilar effect of ketolides and macrolides on erm induction may have several different explanations, including the possibility that ketolides might stall the ribosome at a ''wrong'' place on the ermCL ORF, which is not conducive to ermC induction. Alternatively, ketolides may not induce stalling altogether.
To distinguish between these scenarios, we examined the formation and location of the stalled complex on ermCL mRNA using several different macrolide and ketolide antibiotics (Figure 4) . Substitution of erythromycin with telithromycin eliminated the toe-printing signal, suggesting that some of the structural differences between these two drugs were critical for formation of the stalled complex. Replacement of telithromycin with RU69847, which is isostructural to telithromycin except for the presence of the C3 cladinose, restored stalling, indicating that the presence of the C3 cladinose is critical for the formation of the stalled complex. This result was confirmed using another pair of drugs, HMR3004 and RU66252, which differed only in the presence of cladinose (RU66252) or keto group (HMR3004) at the C3 position of the lactone ring. Here again only the cladinose-containing drug was able to induce stalling.
Ribosomal Elements Critical for Stalling
The cladinose sugar of the ribosome-bound macrolide antibiotics, which, as shown above, is critical for stalling, projects into the tunnel and narrows its opening (Hansen et al., 2002; Schlü nzen et al., 2001 Schlü nzen et al., , 2003 Tu et al., 2005) . On the opposite wall, another protrusion is formed by the base of a universally conserved nucleotide, A2062 of 23S rRNA ( Figure 6A ). A2062 is optimally positioned to directly interact with the critical C-terminal IFVI sequence of the ErmCL nascent peptide ( Figure 6B ). Therefore, this nucleotide was mutated to test its importance for stalling.
Ribosomes with all three possible A2062 mutations could support cell growth when expressed in the E. coli strain that lacked wild-type ribosomes (Asai et al., 1999; Cruz-Vera et al., 2005) . However, in agreement with a previous report (Cochella and Green, 2004) , the A2062G mutant grew very slowly, which prevented using this mutation in our experiments. Importantly, introduction of either A2062U or A2062C mutations in 23S rRNA did not notably affect sensitivity of the cells to erythromycin, indicating that the drug can readily bind to the mutant ribosomes. This The following templates were used: À1, deletion of the Gly2 codon; À2, deletion of Gly2 and Ile3 codons; À3, deletion of Gly2, Ile3, and Phe4 codons; +1, +2, and +3 indicate addition of one, two, or three GCG (Ala) codons after the initiator AUG codon. In (A) and (B), the toe-printing signal corresponding to the stalled complex is indicated by arrows. (B) Efficiency of stalled complex formation on ermCL mRNA with addition or deletion of codons. (C) Quantification of the bands on the gel shown in (B). The plot was obtained by calculating relative intensity of the two stalled complex-specific toeprinting bands versus the sum of these bands and the full (ribosome-free) mRNA band in the same gel.
conclusion was confirmed by RNA footprinting (data not shown). We then tested the ability of A2062U and A2062C mutant ribosomes to translate proteins and induce stalling in the cell-free system. Mutant ribosomes were as active as wild-type ribosomes in translating a control DHFR template (data not shown). However, in contrast to wild-type ribosomes, both mutants, A2062C and A2062U, failed to produce a stalled ErmCL complex in the presence of erythromycin ( Figure 5A ). These results revealed A2062 as a tunnel RNA element critical for drug-dependent ribosome stalling.
In the TnaC and SecM nascent peptides, the identities of amino acid residues located some distance from the PTC were found to be important for stalling (Cruz-Vera et al., 2005; Nakatogawa and Ito, 2002) . In the extended conformation, these segments of the nascent peptides would be close to the b hairpin of protein L22 exposed in the tunnel lumen. Mutational and crystallographic studies led to the proposal that L22 may play an important role in ribosome stalling on secM and tnaC cistrons (Berisio et al., 2003; Cruz-Vera et al., 2005; Naka- Toe-printing analysis of the stalled complex on the ermCL mRNA upon in vitro translation in the presence of 50 mM cladinose-containing macrolide antibiotics (C) or ketolides (K). Lane marked ''À'' corresponds to the reaction carried in the absence of antibiotics. The sequence of a portion of the ermCL ORF and the encoded amino acids are indicated, and the Ile9 codon positioned in the P site of the stalled ribosome is boxed.
The notion that the ErmCL nascent peptide should be of a certain length for drug-dependent stalling to occur ( Figures 3B and  3C ) prompted us to test whether mutations in the L22 b hairpin would also affect ribosome stalling at the ermCL ORF. We employed mutant ribosomes that lack three amino acids (Met82-Arg84) in the L22 b hairpin (Chittum and Champney, 1994) . This deletion does not significantly alter erythromycin binding (Chittum and Champney, 1994; Tu et al., 2005) and thus was suitable for our purposes. Furthermore, L22 mutant ribosomes were as active in translating a control protein template as wildtype ribosomes (data not shown). Toe-printing showed that the 3 amino acid deletion in the L22 b hairpin considerably ($3-fold) reduced the relative amount of the stalled complex formed in the cell-free translation system, therefore implicating involvement of protein L22 in the mechanism of drug-dependent ribosome stalling.
DISCUSSION
The use of the cell-free transcription-translation system provided important insights into the structure of the stalled complex and the molecular mechanism of antibiotic-dependent stalling. Our study made it possible to detect the presence of the stalled ribosome on ermCL mRNA and assess the contribution of the peptide, the drug, and the ribosome on formation of the stalled complex.
Toe-printing placed the Ile9 codon of the ermCL mRNA in the P site of the stalled ribosome, and selective amino acid labeling showed that the C-terminal residue of the nascent peptide is isoleucine. These data revealed the nature of the peptide and the position of the peptidyl-tRNA in the stalled complex and showed that a 9 amino acid-long nascent peptide is esterified to tRNA Ile positioned in the classic P/P site of the ribosome. The inability of puromycin to release the peptide and disassemble the stalled complex hints that the stalled ribosome is unable to catalyze peptide bond formation and that the PTC may be the focal point of the stalling mechanisms. This conclusion is reinforced by the observation that the nature of the amino acid residue that occupies the PTC P site in the stalled complex is critically important-even a conservative change of the C-terminal isoleucine to leucine drastically reduces stalling.
Alanine scanning identified the C-terminal sequence IFVI 9 of the nascent chain as crucial for stalling. Changes in the nascent peptide length, in the structure of the inducing macrolide antibiotic, or even in the ribosome itself can diminish or even completely abolish stalling, but never ''shift'' the stalling site. Thus, the display of this critical 4 amino acid-long C-terminal sequence of the nascent peptide in the PTC-proximal tunnel segment appears to be a necessary prerequisite for the erythromycindependent stalling.
It has long been known that the antibiotic structure is important for erm induction, although the molecular reasons for this were obscure (Mayford and Weisblum, 1990) . Our results show that the cladinose sugar at the C3 position of the macrolide lactone is the specific drug element essential for stalling. The placement of the C3 cladinose in the ribosome-bound antibiotic is such that its direct contact with the IFVI sequence of the nascent peptide is practically unavoidable (Figures 6A and 6B ). This specific drug-peptide interaction likely plays a key role in the mechanism of stalling. Most of the inducible erm genes are preceded by short ORFs that often show only marginal similarity to the ermC leader peptide and are induced by different types of macrolide drugs. Thus the nature of the stalling nascent peptide sequence might be dictated by the chemical structure of the inducing antibiotic. Our finding that the cladinose-lacking antibiotics fail to promote ribosome stalling provides the molecular basis for the clinically relevant observation that ketolides are poor inducers of erm (Bailey et al., 2008; Bonnefoy et al., 1997; Clarebout and Leclercq, 2002; Rosato et al., 1998) .
The narrowing of the tunnel by the cladinose-containing macrolides brings the nascent peptide into a close proximity with a universally conserved 23S rRNA residue, A2062, exposed on the wall of the tunnel precisely at the level with the IFVI sequence ( Figures 6A and 6B) . Our mutational studies showed that the identity of this universally conserved residue is crucial for stalling. Crystallographic studies revealed the mobile nature of A2062 (Hansen et al., 2002) . Two residues that flank A2062, G2061 and C2063, project directly into the PTC active site (Figures 6A and 6C ). G2061 is hydrogen bonded with A2451, one of the key residues in the PTC, and C2063 is hydrogen bonded with its immediate neighbor, A2450. Mutations of either G2061, C2063, A2450, or A2451 are deleterious (Bayfield et al., 2004; Hesslein et al., 2004; Muth et al., 2000) . Because of its link to the PTC residues, A2062 is optimally positioned to sense the nature of the nascent peptide in the exit tunnel and to communicate signals to the PTC. Formation of the stalled complex at the ermCL mRNA requires a nascent peptide of a specific length. A possible interpretation of this finding is that the nascent peptide has to engage more distal elements of the tunnel for a stable complex to form. The loop of protein L22, which is exposed in the tunnel lumen near the N terminus of the extended 9 amino acid-long ErmCL nascent peptide, is an immediate suspect. Not only was the L22 b loop shown to be important for the formation of stalled complexes in SecM and TnaC systems, but alteration of this loop decreased the amount of stalled complex formed on the ermCL template ( Figure 5B ). The flexibility of the L22 b loop and its proposed function in gating the tunnel (Berisio et al., 2003; Tu et al., 2005 ) are in line with its possible contribution to drug-dependent stalling.
Whereas placement of the IFVI sequence too close to the N terminus is not conducive for stalling, moving this sequence too far from the terminus also prevents formation of the stalled complex. This observation is in line with the results of recent studies that showed that erythromycin efficiently promotes drop-off of peptidyl-tRNAs with a nascent peptide exceeding 9 amino acids in length (Lovmar et al., 2004; Tenson et al., 2003) . With the IFVI sequence moved farther away from the N terminus, the ribosome is likely to lose the peptidyl-tRNA before the critical stalling segment of the nascent peptide is synthesized. Thus, in the course of evolution of the ermC induction mechanism, the placement of the IFVI sequence within the ErmCL nascent peptide structure has been carefully optimized: its position within the nascent peptide allows for the peptide N terminus to reach and engage distant elements of the tunnel (possibly protein L22), but it is close enough to the N terminus of the nascent peptide to avoid macrolide-induced peptidyltRNA drop-off prior to synthesis of the stalling sequence.
Combined, our experimental data suggest how the stalling mechanism may operate ( Figure 6D ). Three main players involved in formation of the stalled complex during translation of the ermCL ORF are the drug, the nascent peptide, and the ribosome. A macrolide antibiotic narrows the nascent peptide exit tunnel in the vicinity of the PTC; the presence of a cladinose sugar at the C3 position of the lactone ring is essential to sufficiently reduce the tunnel aperture. Once the IFVI sequence is synthesized during translation of the ermCL ORF, its specific interactions with the drug bring it into the proximity of A2062 and promote reorientation of this trigger residue. The conformational change of A2062 is communicated, likely via its immediate neighbors, G2061 and C2063, to the peptidyl transferase active site ( Figure 6C) . Alternatively, the conformational change can be transmitted to the PTC via the nascent peptide itself. Changes in the PTC conformation prevent formation of the next peptide bond. The side chain of the nascent peptide C-terminal isoleucine located in the P site helps to switch the PTC to an inactive conformation. Engagement of a more distant segment of the tunnel, possibly involving the b loop of protein L22, is essential for either communicating the stalling signal to the PTC or, possibly, for stabilizing the association of peptidyl-tRNA with the stalled complex and preventing rapid drop-off.
Drug-induced ribosome stalling during translation of the ermC leader, though idiosyncratic in many of its features, shares important similarities with the ribosome stalling at secM and tnaC regulatory ORFs (Gong et al., 2001; Nakatogawa and Ito, 2002) . In all three systems the catalytic activity of the PTC is inhibited: the stalled ribosome fails to catalyze peptide bond formation (ermCL and secM) or peptide release (tnaC). The identity of the amino acid residues present in the P site of the PTC (Ile9 for ErmCL, Pro24 for TnaC, Gly165 for SecM) is critical for stalling and may help shape the inactive conformation of the catalytic center. Thus the mechanism of stalling takes advantage of the known ability of the PTC active site to sense the nature of the amino acid residue (Dale and Uhlenbeck, 2005; Krayevsky and Kukhanova, 1979) .
Ribosome stalling at tnaC, secM, or ermCL ORFs requires the presence of an effector that directly or indirectly mediates stalling. Binding of free tryptophan near the PTC A site is thought to drive formation of the stalled complex at the tnaC mRNA (CruzVera et al., 2006; Gong and Yanofsky, 2002) . The presence of Pro-tRNA Pro in the A site of the SecM stalled complex is critical for stalling the ribosome with SecM 1-165 -tRNA Gly bound in the P site (Muto et al., 2006) . In the ErmCL stalled complex, the A site seems to play a less important role. The identity or even the mere presence of aminoacyl-tRNA in the A site is not consequential: missense mutations at the Ser10 codon do not affect stalled complex formation ( Figure 3C ), and nonsense mutations do not alleviate ermC induction (Mayford and Weisblum, 1989) . Instead of an effector in the A site, the ErmCL stalled complex requires the presence of a macrolide molecule in the tunnel. While the A site-bound effectors may help sculpt the inactive conformation of the PTC in the SecM and TnaC stalled complexes, the inducing antibiotic may promote specific interactions of the nascent peptide with the sensory elements of the tunnel during stalling at the ermC leader ORF. The presence of a specific amino acid sequence at the C terminus of the nascent peptide is required for ribosome stalling at the secM and ermCL ORFs. However, there is no obvious similarity between the SecM C-terminal stalling sequence (GIRAG 165 ) (Nakatogawa and Ito, 2002) and the ErmCL stalling sequence IFVI 9 . This is not surprising given that ErmCL and SecM nascent peptides may use different strategies to engage tunnel sensors. The identity of the IFVI sequence of ErmCL is likely dictated by the antibiotic with which this sequence interacts. A particular C-terminal sequence of the SecM nascent peptide appears to promote a specific compact conformation of the nascent peptide in the tunnel (Woolhead et al., 2006) . In such a conformation, the GIRAG sequence of the SecM nascent peptide might come into contact with the same elements of the tunnel (including possibly A2062) that are contacted by the ErmCL peptide IFVI sequence in the presence of antibiotic.
Several rRNA residues of the PTC-proximal segment of the exit tunnel are likely essential in the mechanism of stalling. Two nucleotide residues, A2058 and U2609, were found to be important for stalling at the SecM and TnaC peptides, respectively (Cruz-Vera et al., 2005; Nakatogawa and Ito, 2002) . Interestingly, both of these residues are involved in macrolide binding (Ettayebi et al., 1985; Garza-Ramos et al., 2001; Schlü nzen et al., 2001; Tu et al., 2005) and thus are also involved in the drugdependent stalling at the ermCL ORF. We found here that mutations of A2062 completely eliminate stalling in the ErmCL system. It would be interesting to examine the role of this nucleotide in other stalling bacterial systems. Furthermore, given the nearuniversal conservation of A2062 this residue may be essential even for stalling of eukaryotic ribosomes (Cao and Geballe, 1996; Onouchi et al., 2005; Wang and Sachs, 1997) .
The 9 amino acid ErmCL stalling peptide is much shorter than the nascent peptides in the TnaC and SecM stalled complexes (the latter span the entire length of the tunnel). In spite of this difference, all these nascent peptides appear to form critical interactions at the tunnel constriction. In TnaC and SecM peptides, amino acid residues critical for stalling are located 9-11 residues away from the C terminus (Gong and Yanofsky, 2002; Nakatogawa and Ito, 2002) . The optimal length of the ErmCL peptide in the stalled complex is 9 amino acids, and thus the N-terminal fMet is expected to be placed close to the tunnel segment occupied by the critical residues of SecM and TnaC peptides. The tunnel element that might be universally involved in interaction with these distal sequences of the stalling peptides is the b loop of protein L22 (Figures 5B and 6B) . Indeed, the L22 mutations affect stalling in all of the three systems.
The picture that emerges from comparison of SecM, TnaC, and ErmCL stalling peptides shows that the key components of the stalling mechanism are similar and involve specific elements of the ribosome tunnel, the nascent peptide, and the PTC. Therefore, it appears that the ability to stall or pause in response to a specific nascent peptide sequence is an intrinsic property of the ribosome. Yet the strategies that SecM, TnaC, and ErmCL peptides use to activate stalling are substantially different. This notion hints that nascent peptide-dependent stalling may not be an ''exotic'' trait used for regulation of expression of very few specific genes, but a general mechanism of translation that adjusts the rate of polypeptide synthesis to the specific requirements of expression, folding, and targeting of proteins.
EXPERIMENTAL PROCEDURES
Mutagenesis of rRNA and Preparation of Ribosomes The pLK35 plasmid (Douthwaite et al., 1989) was used for introduction of mutations at A2062 of the 23S rRNA gene. Three possible mutations were introduced using three mutagenizing primers 5 0 -CGGCAAGACGGAAAGXCCC CGTGAACCTTT-3 0 where X was C, U, or G. Mutated plasmids were transformed in POP2136 cells and propagated at 30 C. After the presence of the mutation was verified by sequencing, the mutant plasmids were transformed into SQ171 cells that lack chromosomal copies of rRNA operons (Asai et al., 1999 ) (S. Quan and C.L. Squires, personal communication). Plasmid exchange was done as in Zaporojets et al. (2003) . Mutant cells were grown in 1 liter Luria-Bertani broth to A 600 of 0.6 and harvested, and ribosomes were prepared by the method of Ohashi et al. (2007) .
Cell-free Translation
Construction of DNA templates is described in the Supplemental Experimental Procedures available online. The ''Classic'' PURE cell-free transcription-translation system (Post Genome Institute, Inc., Japan) (Shimizu et al., 2001 ) was used for in vitro protein synthesis (Muto et al., 2006) . In a typical experiment, $0.5-1 pmol of the purified template DNA (plasmid or PCR product) was combined on ice with 6.25 ml of the manufacturer's solution A and 1.25 ml solution B (containing $5-10 pmol ribosomes). When necessary, antibiotics were added from concentrated stocks. The final concentration of erythromycin in most reactions was 50 mM. In experiments when radiolabeling of the translation products was required, 5 mCi of Reactions were typically carried out for 1 hr.
In experiments with mutant ribosomes, the ''D ribosome'' version of the PURE system was supplemented with ribosomes (25 pmol per reaction).
Translation products were analyzed as described in the Supplemental Experimental Procedures.
Model of the Nascent Peptide in the Ribosome
The model of an 8 amino acid-long ErmCL nascent peptide in the ribosome tunnel presented in Tu et al. (2005) was used as a starting point. The ninth amino acid (Ile) and formyl group at the N-terminal methionine were added computationally, and the peptide was translocated down the tunnel to provide the best backbone overlap of the amino acid residues 2-8 of the new peptide with the peptide in the model of Tu et al. The orientation of the side chains and of the N-terminal fMet was manually adjusted to avoid clashes with the tunnel walls and with the antibiotic.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures and can be found with this article online at http://www.molecule.org/cgi/content/full/ 30/2/190/DC1/.
